Clinical trial
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
NCT00027625 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00027625 |
|---|---|
| Title | Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma |
| Official title | A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | gefitinib, temozolomide |
| Start date | Jan 28, 2002 |
| Primary completion | Mar 17, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 27, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: